Donovan T Maust1,2,3, Kenneth M Langa2,3,4,5, Frederic C Blow1,2,3, Helen C Kales1,2,3. 1. Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. 2. Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. 3. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 5. Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.
Abstract
OBJECTIVE: To determine the national prevalence of psychotropic use and association with neuropsychiatric symptoms among patients with dementia. METHODS: Participants diagnosed with dementia (n = 414) in the Aging, Demographics, and Memory Study, a nationally representative survey of US adults >70 years old. Diagnosis was based on in-person clinical assessment and informant interview. Information collected included demographics, place of residence, 10-item Neuropsychiatric Inventory (NPI), and prescribed medications (antipsychotic, sedative-hypnotic, antidepressant, mood stabilizer). RESULTS: Of 414 participants with dementia, 41.4% were prescribed a psychotropic medication, including 84.0% of nursing home residents and 28.6% of community-dwellers. Of participants, 23.5% were prescribed an antidepressant. Compared with the total NPI score of those on no medication (4.5), those on antipsychotics and those on sedative-hypnotics had much higher scores (respectively: 12.6, p < 0.001; 11.8, p = 0.03), although those antidepressants did not (6.9, p = 0.15). A larger proportion of patients on antipsychotics exhibited psychosis and agitation compared with those on no medication, while those on antidepressants exhibited more depressive symptoms. In multivariable logistic regression that included dementia severity and nursing home residence, nursing home residence was the characteristic most strongly associated with psychotropic use (odds ratio ranging from 8.96 [p < 0.001] for antipsychotics to 15.59 [p < 0.001] for sedative-hypnotics). More intense psychotic symptoms and agitation were associated with antipsychotic use; more intense anxiety and agitation were associated with sedative-hypnotic use. More intense depression and apathy were not associated with antidepressant use. CONCLUSIONS: In this nationally representative sample, 41.4% of patients were taking psychotropic medication. While associated with neuropsychiatric symptoms, nursing home residence was most strongly tied to use.
OBJECTIVE: To determine the national prevalence of psychotropic use and association with neuropsychiatric symptoms among patients with dementia. METHODS:Participants diagnosed with dementia (n = 414) in the Aging, Demographics, and Memory Study, a nationally representative survey of US adults >70 years old. Diagnosis was based on in-person clinical assessment and informant interview. Information collected included demographics, place of residence, 10-item Neuropsychiatric Inventory (NPI), and prescribed medications (antipsychotic, sedative-hypnotic, antidepressant, mood stabilizer). RESULTS: Of 414 participants with dementia, 41.4% were prescribed a psychotropic medication, including 84.0% of nursing home residents and 28.6% of community-dwellers. Of participants, 23.5% were prescribed an antidepressant. Compared with the total NPI score of those on no medication (4.5), those on antipsychotics and those on sedative-hypnotics had much higher scores (respectively: 12.6, p < 0.001; 11.8, p = 0.03), although those antidepressants did not (6.9, p = 0.15). A larger proportion of patients on antipsychotics exhibited psychosis and agitation compared with those on no medication, while those on antidepressants exhibited more depressive symptoms. In multivariable logistic regression that included dementia severity and nursing home residence, nursing home residence was the characteristic most strongly associated with psychotropic use (odds ratio ranging from 8.96 [p < 0.001] for antipsychotics to 15.59 [p < 0.001] for sedative-hypnotics). More intense psychotic symptoms and agitation were associated with antipsychotic use; more intense anxiety and agitation were associated with sedative-hypnotic use. More intense depression and apathy were not associated with antidepressant use. CONCLUSIONS: In this nationally representative sample, 41.4% of patients were taking psychotropic medication. While associated with neuropsychiatric symptoms, nursing home residence was most strongly tied to use.
Authors: Brenda L Plassman; Kenneth M Langa; Ryan J McCammon; Gwenith G Fisher; Guy G Potter; James R Burke; David C Steffens; Norman L Foster; Bruno Giordani; Frederick W Unverzagt; Kathleen A Welsh-Bohmer; Steven G Heeringa; David R Weir; Robert B Wallace Journal: Ann Neurol Date: 2011-03-18 Impact factor: 10.422
Authors: Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2010-02 Impact factor: 4.105
Authors: Krista F Huybrechts; Kenneth J Rothman; Rebecca A Silliman; M Alan Brookhart; Sebastian Schneeweiss Journal: CMAJ Date: 2011-03-28 Impact factor: 8.262
Authors: Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller Journal: Alzheimers Dement Date: 2011-09 Impact factor: 21.566
Authors: Amanda Sonnega; Jessica D Faul; Mary Beth Ofstedal; Kenneth M Langa; John W R Phillips; David R Weir Journal: Int J Epidemiol Date: 2014-03-25 Impact factor: 7.196
Authors: Kenneth Rockwood; Susan E Howlett; Chris MacKnight; B Lynn Beattie; Howard Bergman; Réjean Hébert; David B Hogan; Christina Wolfson; Ian McDowell Journal: J Gerontol A Biol Sci Med Sci Date: 2004-12 Impact factor: 6.053
Authors: G C Román; T K Tatemichi; T Erkinjuntti; J L Cummings; J C Masdeu; J H Garcia; L Amaducci; J M Orgogozo; A Brun; A Hofman Journal: Neurology Date: 1993-02 Impact factor: 9.910
Authors: Lauren B Gerlach; Donovan T Maust; Helen C Kales; Myron Chang; H Myra Kim; Ilse R Wiechers; Kara Zivin Journal: Am J Psychiatry Date: 2022-05-26 Impact factor: 19.242
Authors: Ryan M Silwanowicz; Donovan T Maust; Lisa S Seyfried; Claire Chiang; Claire Stano; Helen C Kales Journal: Int J Geriatr Psychiatry Date: 2016-10-04 Impact factor: 3.485
Authors: Barbara Resnick; Ann Kolanowski; Kimberly Van Haitsma; Elizabeth Galik; Marie Boltz; Jeanette Ellis; Liza Behrens; Karen Eshraghi; Shijun Zhu Journal: Clin Nurs Res Date: 2019-04-03 Impact factor: 2.075
Authors: Elizabeth M Galik; Barbara Resnick; Sarah D Holmes; Erin Vigne; Karen Lynch; Jeanette Ellis; Shijun Zhu; Erik Barr Journal: J Am Med Dir Assoc Date: 2021-01-15 Impact factor: 7.802
Authors: Sebastian Rios; Christopher M Perlman; Andrew Costa; George Heckman; John P Hirdes; Lori Mitchell Journal: BMC Geriatr Date: 2017-10-23 Impact factor: 3.921
Authors: Barbara Resnick; Marie Boltz; Elizabeth Galik; Sarah Holmes; Steven Fix; Shijun Zhu Journal: Res Gerontol Nurs Date: 2019-10-04 Impact factor: 1.571
Authors: Donovan T Maust; Julie Strominger; H Myra Kim; Kenneth M Langa; Julie P W Bynum; Chiang-Hua Chang; Helen C Kales; Kara Zivin; Erica Solway; Steven C Marcus Journal: JAMA Date: 2021-03-09 Impact factor: 56.272